Local injection of stem cells or endothelial progenitors directly into the ischaemic tissue remains an option for the management of arterial occlusion. Bone marrow-derived mesenchymal stem cells (MSCs) represent a promising alternative autologous cell source for ischaemic limb cell therapy. However, methods for applying MSCs in allogeneic transplantation remain to be developed. The purpose of this study was to evaluate the therapeutic potential of MSCs cultured under a different environment in ameliorating limb ischaemia in allogeneic recipients.
Introduction
The management of acute arterial occlusion remains a challenge for vascular surgeons. One therapeutic approach involves local injection of stem cells or endothelial progenitors directly into the ischaemic tissue. However, to efficiently improve limb perfusion, a large number of cells are required for immediate transplantation. Given their ease of isolation, amenability to ex vivo expansion, and genetic modification, 1 bone marrow-derived multipotent stromal cells, or mesenchymal stem cells (MSCs) evidently represent a promising alternative autologous cell source for ischaemic limb cell therapy. 2 Using an 'off-the-shelf' product from the MSCs of a single, healthy donor cell has proved safe in two Phase III studies in patients with graft-vs.-host disease and Crohn's disease. 3 Moreover, improvement in ejection fractions was also reported in patients with acute myocardial infarction treated with allogeneic MSCs. 4 Thus, allogeneic MSCs from healthy donors may serve as a 'universal donor cell' to treat patients with cardiovascular diseases. However, many studies have demonstrated that MSCs are not intrinsically immunoprivileged and allogeneic MSCs are rejected in immunocompetent major histocompatibility complex (MHC)-mismatched recipients. 5 -7 Thus, the use of MSCs for allogeneic transplantation remains controversial. Especially in the long term, MSCs cultured under hypoxic conditions, here referred to as hypoxic MSCs, have a decreased replicative senescence, but increased proliferation rate and differentiation potential, compared with MSCs expanded under normoxic conditions, here referred to as normoxic MSCs. 8 Hypoxic MSCs also secrete more angiogenic cytokines and growth factors than normoxic MSCs 9 do, and the conditioned medium derived from hypoxic MSCs have been applied to prevent sudden arrhythmic death in rodents. 10 These results suggest that hypoxic culture provides various benefits in cultured MSCs. However, it remains unknown whether hypoxic MSCs have an increased ability to survive and engraft in allogeneic host tissues. Therefore, the aim of the current study was to examine whether syngeneic or allogeneic transplantation of hypoxic or normoxic MSCs improved limb perfusion compared with vehicle control in a mouse limb ischaemia model. We then aimed to establish whether the improvement of limb perfusion by cell transplantation was also observed when non-MSCs were used. We further compared the effects of hypoxic and normoxic MSCs on improving limb perfusion either in syngeneic or allogeneic transplantation. Moreover, we specifically analysed whether hypoxic MSCs increased survival compared with normoxic MSCs at 7 days after transplantation. Finally, we elucidated the mechanism used by hypoxic MSCs to survive after transplantation and to improve limb perfusion in allogeneic recipients.
Methods

MSC isolation, characterization, and culture
The study was conducted in accordance with the Declaration of Helsinki. MSCs were isolated from human bone marrow with informed consent and approved by the Institutional Review Board of Taipei Veterans General Hospital. Mouse MSCs were obtained from 4-to 6-week-old male C57BL/6J (B6) and Balb/c mice. For isolation of mouse MSCs, all tibiae and femurs with the ends clipped to expose the marrow were inserted into adapted centrifuge tubes and centrifuged at 400 g for 1 min to collect the marrow. The pellet was resuspended in 3 mL complete medium [CM: a-minimum essential medium supplemented with 16.6% foetal bovine serum (FBS), 100 U/mL penicillin, and 100 g/mL streptomycin], filtrated through a 70 mm nylon mesh filter, and seeded in dishes. After 24 h, nonadherent cells were removed by washing with phosphate-buffered saline (PBS), and 10 mL of fresh CM was added. Adherent cells reached subconfluence around 2 weeks and were washed with PBS and detached by incubation in 4 mL of 0.25% trypsin/1 mM ethylenediaminetetraacetic acid (Invitrogen, Carlsbad, CA, USA) at 378C for 2 min. The cells were then expanded by plating at 50 -100 cells/cm 2 in CM and subcultured at 10 days. The cells were used in these studies up to Passage 3. For hypoxic culture, cells were cultured in a gas mixture composed of 94% N 2 , 5% CO 2 , and 1% O 2 .
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Flow cytometry analysis and differentiation assays were performed with standard protocols (see Supplementary material online, Materials and methods).
Ischaemic limb models and evaluation of limb perfusion were performed with standard protocols (see Supplementary material online, Materials and methods).
Immunohistochemistry, immunofluorescence, and immunoblotting were performed with standard protocols (see Supplementary material online, Materials and methods).
NK cytotoxicity assay
For purification of natural killer (NK) cells by magnetic cell separation system (MACS), splenocytes were incubated with the NK cell isolation kit (Miltenyi Biotec, Auburn, CA, USA), and cells were sorted by autoMACS (Miltenyi Biotec). NK cells were expanded in NK cell media, consisting of RPMI 1640 containing 10% FBS and penicillin/streptomycin, in the presence or absence of 1000 U/mL of IL-2 (BioLegend, San Diego, CA, USA) for 5 days. The cytotoxic activities of NK cells to MSCs were determined using the Promega CytoTox 96 Non-Radioactive Cytotoxicity Assay kit, 12 measuring lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released upon cell lysis. Effector (E) cells (NKs) were incubated with 
Results
Characterization of MSCs cultured under hypoxic and normoxic conditions
Both hypoxic and normoxic MSCs from either B6 or Balb/c mice expressed markers of MSCs including Sca1, CD29, CD44, and CD105, but did not express markers for haematopoietic cells, such as CD11b, CD34 and CD45, and endothelial markers, such as CD31 ( Figure 1A and Supplementary material online, Figure S1A ). Moreover, hypoxic and normoxic MSCs from either B6 or Balb/c mice showed a similar ability to differentiate into osteogenic, adipogenic, and chondrogenic lineages ( Figure 1B and Supplementary material online, Figure S1B ). The hypoxic status of the MSCs cultured under hypoxic conditions was confirmed by the increased expression of several hypoxia-inducible factor 1-regulated factors, such as SDF1, CXCR4, or vascular endothelial growth factor (VEGF), compared with normoxic MSCs (Supplementary material online, Figure S2A ). In addition, hypoxia also increased the mRNA levels of some immune tolerance-related factors, such as Idol1, IL10, and Tgfb1, before transplantation (Supplementary material online, Figure S2B ). These data suggest that there are no obvious differences between hypoxic and normoxic MSCs in terms of surface protein profile and differentiation potentials at early passages.
Allogeneic transplantation of hypoxic MSCs increases limb ischaemia improvement compared with normoxic MSCs
The angiogenic potential of MSCs at Passage 3 or less was evaluated in a Balb/c mouse model of hindlimb ischaemia, following the experimental protocol shown in Figure 2A . At 1 -2 weeks after injection, the control (no cell, vehicle alone) group showed extensive necrosis of the ischaemic hindlimb, resulting in limb loss by autoamputation ( Figure 2B ). At 4 weeks, there were seven cases of limb loss in the control group (87.5%) and one of limb necrosis (12.5%) of eight mice ( Figure 2C ). Similarly, the non-MSC (MEF Balb/c) group had six cases of limb loss (75%) and two of limb necrosis (25%) of eight mice ( Figure 2C ). Figure 2C ). The evaluation of blood perfusion by LDPI analysis further revealed that limb perfusion in both the control and the non-MSC group decreased as time increased, while perfusion in mice receiving hypoxic or normoxic MSCs from either B6 or Balb/c increased along with the increase of time ( Figure 2D and E). Moreover, perfusion in mice receiving Hypoxic MSCs escape NK lysis hypoxic or normoxic MSCs from either B6 or Balb/c, but not non-MSCs, increased 1 or 2 weeks after transplantation compared with no cell control ( Figure 2D and E). This suggests that the ability of transplanted cells to increase perfusion is limited to MSCs, but is independent of donor type or culture condition. In mice receiving syngeneic MSCs (Balb/c), there was no difference in perfusion between hypoxic and normoxic MSCs ( Figure 2D and E). In mice receiving allogeneic MSCs (B6), hypoxic MSCs increased limb perfusion 1 week after transplantation compared with normoxic MSCs (Figure 2D and E) , suggesting that the culture condition determines the effect of allogeneic MSCs on improving perfusion. When hypoxic MSCs were transplanted, there was no difference in perfusion increase between syngeneic and allogeneic donors ( Figure 2D and E) . When normoxic MSCs were transplanted, perfusion was increased in the syngeneic MSCs 1 week after transplantation compared with the allogeneic MSCs ( Figure 2D and E). These data suggest that ischaemic limbs transplanted with hypoxic MSCs from allogeneic donors, or both normoxic and hypoxic MSCs from syngeneic donors recovered with near-normal perfusion, while those transplanted with normoxic MSCs from allogeneic donors still had significant limb perfusion impairment.
Hypoxic MSCs decrease muscle degeneration and fibrosis and increase angiogenesis of the ischaemic limb
Histological analysis with haematoxylin and eosin (H&E) staining of the gracilis muscle retrieved at 4 weeks after the induction of limb ischaemia revealed that mice receiving hypoxic MSCs from B6, or hypoxic or normoxic MSCs from Balb/c, maintained normal muscular tissue without loss of muscle fibres, while those receiving normoxic MSCs from B6 still experienced muscle atrophy with loss of some fibres ( Figure 3A) . However, the control and the non-MSC group had marked muscle fibre loss and muscle atrophy with fatty degeneration ( Figure 3A) . Following quantitation of muscle loss by measuring the ratio of non-muscle area to total area in the experimental specimens, we found that the ratios of muscle loss were 3.32 + 0.014%) or normoxic MSCs (0.28 + 0. 14%) from Balb/c showed no muscle fibrosis, whereas those receiving normoxic MSCs from B6 mice (9.39 + 1.07%) still experienced some muscle fibrosis ( Figure 3A and C ). However, mice that received non-MSC (22.93 + 3.99%) or no cell transplantation (30.14 + 11.59%) showed marked muscle fibrosis ( Figure 3A and C Figure 3A and D) . These data demonstrate that the therapeutic contribution of allogeneic MSC transplantation to muscle regeneration and neovascularization was significantly enhanced in MSCs cultured under hypoxic conditions.
Hypoxic MSCs survive and engraft after transplantation
The early fate of transplanted MSCs was investigated using short-term labelling with carboxyfluorescein diacetate succinimidyl ester (CFSE), 13 clearly showing the presence of CFSE-labelled cells in ischaemic tissues of mice receiving hypoxic MSCs from B6, or hypoxic or normoxic MSCs from Balb/c, but not in tissues of mice that received normoxic MSCs from B6 at 7 days of transplantation ( Figure 4A) . Moreover, double immunofluorescence of active caspase 3 and H2Kb, a class I MHC of B6, at 7 days after transplantation further revealed that the hypoxic culture condition increased the anti-apoptotic ability in MSCs compared with the normoxic culture condition (Supplementary material online, Figure S3 ). This suggests that allogeneic normoxic MSCs were killed early after transplantation. Immunofluorescence of Ki-67 further revealed that CFSE-labelled MSCs did not express Ki-67 ( Figure 4B) Figure 5A ). Double immunofluorescence for BrdU and CD31 showed that some BrdU+ cells were observed in the CD31+ vessels with red blood cells in their lumens ( Figure 5B), indicating that some transplanted cells were incorporated into neovessels and indeed functioned and contributed to blood perfusion. Double immunofluorescence for BrdU and a-smooth muscle actin (a-SMA) or desmin ( Figure 5C and D) showed that some BrdU+ cells were also positive for a-SMA or desmin in the ischaemic regions, suggesting some transplanted cells differentiated into muscle tissues. or desmin+ cells (Supplementary material online, Figure S4 ). These results suggest that transplanted allogeneic hypoxic MSCs survived after transplantation, engrafted into mouse tissue, and subsequently induced vascular and muscular networks in the ischaemic muscles.
Hypoxic MSCs decrease in NK accumulation in allogeneic recipients
The anti-NKp46 and anti-DX5 antibodies were used to identify NK cells at 7 days of transplantation. The ischaemic muscle tissue injected with hypoxic MSCs from B6, or hypoxic or normoxic MSCs from Balb/c, did not reveal NKp46+ or DX5+ NK accumulation, while normoxic MSCs from B6 accumulated NKp46+ or DX5+ NK cells ( Figure 6A and Supplementary material online, Figure S5A ). However, immunofluorescence showed that neither hypoxic nor normoxic MSCs from B6 or Balb/c accumulated CD3+, CD4+, or CD8+ T cells, CD14+ or Mac3+ macrophages, CD86+ dendritic cells, or TCRab+ NKT cells (Supplementary material online, Figure S5A ). Moreover, immunofluorescence further showed the co-expression of the activated marker CD69 in the accumulated NK cells (Supplementary material online, Figure S5B ), suggesting the involvement of NK accumulation and activation in the killing of normoxic MSCs in allogeneic recipients. To analyse whether this was a general phenomenon independent of mice strain, we evaluated the effects of transplanted normoxic MSCs on ameliorating limb ischaemia in allogeneic recipients without and with NK depletion using B6 to Bal/c, and vice versa. NK depletion via co-injection with neutralization antibodies against asialo GM1 and NK1.1 14 greatly improved normoxic B6 and Balb/c MSC-mediated improvement of limb ischaemia in allogeneic recipients, respectively ( Figure 6B and C ). These data suggest the involvement of NK-mediated lysis in the rejection of allogeneic MSCs after transplantation.
Hypoxic MSCs escape NK lysis
Hypoxic culture suppressed NK-mediated lysis in the presence of IL-2 ( Figure 6D) . NK in the presence of IL-2 induced 84.15% lysis of normoxic MSCs, while it only induced 0.44% lysis of hypoxic MSCs ( Figure 6D) . Similar results were obtained with experiments using MSCs from Balb/c and NK cells from B6 ( Figure 6E) . Consistently, allogeneic NK cellmediated lysis was observed in human normoxic MSCs, but not in human hypoxic MSCs ( Figure 6F ). These data suggest that hypoxic, but not normoxic, MSCs escape lysis of allogeneic NK independent of mouse strains or species variation.
Discussion
In the current study, we demonstrated that allogeneic hypoxic MSCs increase the therapeutic effects in ameliorating limb ischaemia compared with allogeneic normoxic MSCs. The effects were similar with syngeneic hypoxic and normoxic MSCs. Moreover, these cells gave rise to CD31+ endothelial cells, a-SMA+, and desmin+ muscle cells, thereby enhancing angiogenesis and inhibiting muscle fibrosis. There were no differences between the surface protein profiles and differentiation potentials of hypoxic and normoxic MSCs used in this study (less than Passage 3). Most importantly, there were no differences between hypoxic and normoxic MSCs from syngeneic donors in improving limb perfusion and engrafting into muscle and endothelial cells. Thus, the discrepancy between hypoxic and normoxic MSCs from allogeneic donors in improving limb perfusion, and engraftment was not caused by changes in population differences or differentiation potentials between these cells. Moreover, the LDPI data diverged in favour of hypoxic allogeneic MSCs at 1 week, when no normoxic allogeneic MSCs were observed in the recipient limbs, suggesting that engraft of MSCs is the prerequisite for transplanted MSCs to have effects on improving blood perfusion in a later stage. Although the therapeutic use of allogeneic MSCs has been studied in animal studies and clinical trials, 15 Details of the components of the immune system such as NK, cytotoxic T, and NKT involved in the tolerance or rejection of grafts have been clarified. Rejection of MHC different grafts, bone marrow cells, or purified haematopoietic stem cells (HSCs) by irradiated mice is chiefly mediated by NK cells rather than by cytotoxic T cells. 17 -19 Huang et al. 18 demonstrated that MHC Class I plays a critical role in initiating events dictating HSC engraftment, and MHC Class I disparitymediated rejection is mainly executed by NK following allogeneic transplantation. More recently, it has also been reported that NK not only mediates immune rejection of bone marrow transplantation, but also participates in the acute rejection of cardiac allografts and in the development of cardiac allograft vasculopathy. 20 The current study demonstrated that MSCs, similar to HSCs or other bone marrow grafts, were also rejected by NK-mediated lysis in allogeneic recipients. Interestingly, we found that hypoxic MSCs were engrafted into allogeneic recipients and expressed markers of muscular and endothelial cells. Previously, MSCs derived from induced pluripotent cells also differentiated into muscular and endothelial cells when injected into ischaemic limbs. 21 The present study is the first to demonstrate whether bone marrow MSCs possess multiple differentiation potentials into functional endothelial or muscular cells in allogeneic recipients. Except for multiple differentiation potential, hypoxic MSCs have been demonstrated to have a greater role in supporting angiogenesis than normoxic MSCs have by secreting paracrine factors such as IL-6 and VEGF both in vitro 9 and in vivo.
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Thus, the beneficial effect of hypoxic MSCs on ischaemic tissues may be attributable not only to their participation in the vascular structures, but also to their ability to produce pro-angiogenic factors.
There is cumulative evidence that inflammatory cells such as CD4+ and CD8+ T lymphocytes induce collateral formation and blood flow recovery. However, there is little, if any, difference in the appearance of these two cells in the limbs that received either allogeneic hypoxic or normoxic MSCs. Because MSCs have been shown to suppress proliferation or induce apoptosis in T lymphocytes, 23 these data thus suggested that MSCs did not improve limb perfusion through recruiting CD4+ and CD8+ T lymphocytes. Similarly, it has been shown that NK cells also assist in blood perfusion in ischaemic limb and the administration of anti-NK1.1 antibodies to deplete NK cells hampered blood flow recovery, 24 advising NK cells induced collateral formation and blood flow recovery. However, our data showed that allogeneic normoxic MSCs, rather than allogeneic hypoxic MSCs, cause the accumulation of NK cells in ischaemic limb, and that NK depletion provoked an increase in blood perfusion in limbs receiving allogeneic normoxic MSCs. Thus, these data suggest that allogeneic hypoxic MSCs do not improve limb perfusion through recruiting NK cells. MSCs have been reported to secrete paracrine factors in modulating host responses to injury or degeneration. 25 Because the mRNA levels of several immune tolerance-related factors, such as idol1, IL-10, and Tgfb1, 26 were increased in hypoxic MSCs from Balb/c and B6 before transplantation, we were not able to exclude the possibility that paracrine effects of allogeneic hypoxic MSCs contributed to their increased ability to tolerate or escape host immune rejection. However, this issue is complex to address because the mRNA levels analysed before transplantation may not be used to predict the mRNA levels of those cells after transplantation, especially when transplanted into an area with reduced oxygen tension, such as ischaemic limb used in the current study, which would change the transcription profiles of transplanted cells. Further studies should be designed to elucidate the roles of paracrine effects of transplanted stem or progenitor cells in ameliorating limb ischaemia. Hypoxic MSCs could be an alternative cell source for use in therapeutic angiogenesis to treat ischaemic diseases. First, these cells could provide functional endothelial and muscular cells that would be available for clinical application in unlimited amounts. It has been reported that the number of endothelial progenitor cells in adult bone marrow or peripheral blood is limited. 27 Moreover, endothelial cells or progenitor cells usually have limited proliferative capacity, and thus, expansion of a sufficient number of cells for transplantation remains a major task. 28 In contrast, hypoxic MSCs have an extended self-renewal activity and can be expanded up to 12 weeks without significant loss of stem cell properties. 8 Secondly, hypoxic MSCs show low immunogenicity in vivo and are less susceptible to immune rejection than normoxic MSCs. Thus, hypoxic MSCs and their derivatives may be suitable for allogeneic transplantation. Current studies have demonstrated that hypoxic MSCs inhibited the accumulation and cytotoxicity of NK cells, thus, increasing the ability to survive and engraft allogeneic recipients. In summary, allogeneic hypoxic MSC therapy has been tested in an immune-competent animal model as a preclinical study to prove its therapeutic potential and immune benefits in treating severe ischaemic diseases. These data may help develop new strategies in applying MSCs for allogeneic transplantation in clinical trials.
